Soluble peptidoglycan-induced monokine production can be blocked by anti- CD14 monoclonal antibodies and by lipid A partial structures

B. Weidemann, H. Brade, E. T. Rietschel, Roman Dziarski, V. Bazil, S. Kusumoto, H. D. Flad, A. J. Ulmer

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

We have investigated the interaction of soluble peptidoglycan (sPG), in comparison with lipopolysaccharide (LPS), with human mononuclear cells (MNC) by determining the capacity of sPG to induce interleukin-6 (IL-6) and IL-1 release. In addition, we investigated the modulation of their interaction by anti-CD14 monoclonal antibody and by partial structures of LPS. We found that sPG, like LPS, was able to induce IL-6 and IL-1 production by MNC. However, dose-response experiments revealed that at least 3,000 ng of sPG per ml was necessary for induction, whereas the optimal LPS concentration was 1 ng/ml. Anti-CD14 monoclonal antibody reduced sPG- and LPS-induced IL-6 and IL-1 production. Moreover, partial structures of LPS were able to reduce monokine production induced by sPG and LPS. We conclude that sPG constitutes, like LPS, an inflammatory cytokine inducer and that CD14 is involved in the activation of human monocytes not only by LPS but also by sPG.

Original languageEnglish (US)
Pages (from-to)4709-4715
Number of pages7
JournalInfection and Immunity
Volume62
Issue number11
StatePublished - 1994
Externally publishedYes

Fingerprint

Monokines
Lipid A
Peptidoglycan
Lipopolysaccharides
Monoclonal Antibodies
Interleukin-1
Interleukin-6
Monocytes
Cytokines

ASJC Scopus subject areas

  • Immunology

Cite this

Weidemann, B., Brade, H., Rietschel, E. T., Dziarski, R., Bazil, V., Kusumoto, S., ... Ulmer, A. J. (1994). Soluble peptidoglycan-induced monokine production can be blocked by anti- CD14 monoclonal antibodies and by lipid A partial structures. Infection and Immunity, 62(11), 4709-4715.

Soluble peptidoglycan-induced monokine production can be blocked by anti- CD14 monoclonal antibodies and by lipid A partial structures. / Weidemann, B.; Brade, H.; Rietschel, E. T.; Dziarski, Roman; Bazil, V.; Kusumoto, S.; Flad, H. D.; Ulmer, A. J.

In: Infection and Immunity, Vol. 62, No. 11, 1994, p. 4709-4715.

Research output: Contribution to journalArticle

Weidemann, B, Brade, H, Rietschel, ET, Dziarski, R, Bazil, V, Kusumoto, S, Flad, HD & Ulmer, AJ 1994, 'Soluble peptidoglycan-induced monokine production can be blocked by anti- CD14 monoclonal antibodies and by lipid A partial structures', Infection and Immunity, vol. 62, no. 11, pp. 4709-4715.
Weidemann, B. ; Brade, H. ; Rietschel, E. T. ; Dziarski, Roman ; Bazil, V. ; Kusumoto, S. ; Flad, H. D. ; Ulmer, A. J. / Soluble peptidoglycan-induced monokine production can be blocked by anti- CD14 monoclonal antibodies and by lipid A partial structures. In: Infection and Immunity. 1994 ; Vol. 62, No. 11. pp. 4709-4715.
@article{9d4f691955f542adb58b4213e8a10041,
title = "Soluble peptidoglycan-induced monokine production can be blocked by anti- CD14 monoclonal antibodies and by lipid A partial structures",
abstract = "We have investigated the interaction of soluble peptidoglycan (sPG), in comparison with lipopolysaccharide (LPS), with human mononuclear cells (MNC) by determining the capacity of sPG to induce interleukin-6 (IL-6) and IL-1 release. In addition, we investigated the modulation of their interaction by anti-CD14 monoclonal antibody and by partial structures of LPS. We found that sPG, like LPS, was able to induce IL-6 and IL-1 production by MNC. However, dose-response experiments revealed that at least 3,000 ng of sPG per ml was necessary for induction, whereas the optimal LPS concentration was 1 ng/ml. Anti-CD14 monoclonal antibody reduced sPG- and LPS-induced IL-6 and IL-1 production. Moreover, partial structures of LPS were able to reduce monokine production induced by sPG and LPS. We conclude that sPG constitutes, like LPS, an inflammatory cytokine inducer and that CD14 is involved in the activation of human monocytes not only by LPS but also by sPG.",
author = "B. Weidemann and H. Brade and Rietschel, {E. T.} and Roman Dziarski and V. Bazil and S. Kusumoto and Flad, {H. D.} and Ulmer, {A. J.}",
year = "1994",
language = "English (US)",
volume = "62",
pages = "4709--4715",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Soluble peptidoglycan-induced monokine production can be blocked by anti- CD14 monoclonal antibodies and by lipid A partial structures

AU - Weidemann, B.

AU - Brade, H.

AU - Rietschel, E. T.

AU - Dziarski, Roman

AU - Bazil, V.

AU - Kusumoto, S.

AU - Flad, H. D.

AU - Ulmer, A. J.

PY - 1994

Y1 - 1994

N2 - We have investigated the interaction of soluble peptidoglycan (sPG), in comparison with lipopolysaccharide (LPS), with human mononuclear cells (MNC) by determining the capacity of sPG to induce interleukin-6 (IL-6) and IL-1 release. In addition, we investigated the modulation of their interaction by anti-CD14 monoclonal antibody and by partial structures of LPS. We found that sPG, like LPS, was able to induce IL-6 and IL-1 production by MNC. However, dose-response experiments revealed that at least 3,000 ng of sPG per ml was necessary for induction, whereas the optimal LPS concentration was 1 ng/ml. Anti-CD14 monoclonal antibody reduced sPG- and LPS-induced IL-6 and IL-1 production. Moreover, partial structures of LPS were able to reduce monokine production induced by sPG and LPS. We conclude that sPG constitutes, like LPS, an inflammatory cytokine inducer and that CD14 is involved in the activation of human monocytes not only by LPS but also by sPG.

AB - We have investigated the interaction of soluble peptidoglycan (sPG), in comparison with lipopolysaccharide (LPS), with human mononuclear cells (MNC) by determining the capacity of sPG to induce interleukin-6 (IL-6) and IL-1 release. In addition, we investigated the modulation of their interaction by anti-CD14 monoclonal antibody and by partial structures of LPS. We found that sPG, like LPS, was able to induce IL-6 and IL-1 production by MNC. However, dose-response experiments revealed that at least 3,000 ng of sPG per ml was necessary for induction, whereas the optimal LPS concentration was 1 ng/ml. Anti-CD14 monoclonal antibody reduced sPG- and LPS-induced IL-6 and IL-1 production. Moreover, partial structures of LPS were able to reduce monokine production induced by sPG and LPS. We conclude that sPG constitutes, like LPS, an inflammatory cytokine inducer and that CD14 is involved in the activation of human monocytes not only by LPS but also by sPG.

UR - http://www.scopus.com/inward/record.url?scp=0028114530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028114530&partnerID=8YFLogxK

M3 - Article

C2 - 7523297

AN - SCOPUS:0028114530

VL - 62

SP - 4709

EP - 4715

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 11

ER -